← Leaderboards
Philip Lazarus
Washington State University
$12,603,602
Attributed
$13,580,341
Total exposure
7
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $977.7K · FY2005–25$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$15,337,705 · 8
By mechanism
R01$12,317,881 · 6
P01$3,019,824 · 2
Top collaborators
- Jian-Min Yuan3 shared
Most similar at Washington State University
Same institution · by research overlap
- Jian-Min Yuan$29,275,563
Others in their field
Top investigators on “Glucuronosyltransferase”
- Robert H Tukey · University Of California San Diego$11,818,423
- M. Peter Lance · University Of Arizona$9,350,950
- Stephen Marc Schwartz · Fred Hutchinson Cancer Research Center$6,502,051
- Ming Hu · Washington State University$5,453,576
- Lang Li · Indiana Univ-Purdue Univ At Indianapolis$4,522,266
- Johanna W Lampe · Fred Hutchinson Cancer Research Center$4,446,818
Research focus
GlucuronosyltransferaseGenetic PolymorphismCancer RiskGenotypePhenotypeMicrosomesTissuesEnzymesLiverPlayGenesCell LineVariantCarcinogenesisProteinsIn VitroMalignant NeoplasmsKineticsCarcinogensLungNitrosaminesMalignant Neoplasm Of LungGlucuronidesPredisposition
Grant awards (37)
Gene-tobacco carcinogen interactions and lung cancer risk - a novel approach for precision cancer prevention$680,190
R01 · FY2025 · CA · contact PI
Gene-tobacco carcinogen interactions and lung cancer risk - a novel approach for precision cancer prevention$605,270
R01 · FY2024 · CA · contact PI
Gene-tobacco carcinogen interactions and lung cancer risk - a novel approach for precision cancer prevention$668,019
R01 · FY2023 · CA · contact PI
The UGT2A and 3A metabolizing enzymes and tobacco-related cancer risk$586,231
R01 · FY2019 · ES · contact PI
The UGT2A and 3A metabolizing enzymes and tobacco-related cancer risk$569,922
R01 · FY2018 · ES · contact PI
The UGT2A and 3A metabolizing enzymes and tobacco-related cancer risk$626,582
R01 · FY2017 · ES · contact PI
Role of pharmacogenetics on exemestane metabolism and toxicity$465,866
R01 · FY2016 · CA · contact PI
The UGT2A and 3A metabolizing enzymes and tobacco-related cancer risk$459,733
R01 · FY2016 · ES · contact PI
The UGT2A and 3A metabolizing enzymes and tobacco-related cancer risk$52,100
R01 · FY2016 · ES · contact PI
Role of pharmacogenetics on exemestane metabolism and toxicity$466,040
R01 · FY2015 · CA · contact PI
The UGT2A and 3A metabolizing enzymes and tobacco-related cancer risk$459,733
R01 · FY2015 · ES · contact PI
Role of pharmacogenetics on exemestane metabolism and toxicity$445,810
R01 · FY2014 · CA · contact PI
Role of pharmacogenetics on exemestane metabolism and toxicity$513,347
R01 · FY2013 · CA · contact PI
Role of pharmacogenetics on exemestane metabolism and toxicity$527,272
R01 · FY2012 · CA · contact PI
UDP-GLUCURONOSYLTRANSFERASE GENOTYPE AND CANCER RISK$502,687
R01 · FY2011 · DE · contact PI
UDP-GLUCURONOSYLTRANSFERASE GENOTYPE AND CANCER RISK$507,677
R01 · FY2010 · DE · contact PI
UDP-GLUCURONOSYLTRANSFERASE GENOTYPE AND CANCER RISK$497,789
R01 · FY2009 · DE · contact PI
UDP-GLUCURONOSYLTRANSFERASE GENOTYPE AND CANCER RISK$483,110
R01 · FY2008 · DE · contact PI
UDP-GLUCURONOSYLTRANSFERASE GENOTYPE AND CANCER RISK$474,247
R01 · FY2007 · DE · contact PI
Analysis of 5'UTR-Mediated Regulation of p53 Expression$277,746
R01 · FY2006 · CA · contact PI
TOBACCO AND CANCER RISK--DOSE, METABOLISM AND GENETICS$529,688
P01 · FY2005 · CA
Analysis of 5'UTR-Mediated Regulation of p53 Expression$284,430
R01 · FY2005 · CA
TOBACCO AND CANCER RISK--DOSE, METABOLISM AND GENETICS$1,227,676
P01 · FY2004 · CA
Analysis of 5'UTR-Mediated Regulation of p53 Expression$284,430
R01 · FY2004 · CA
UDPGLUCURONOSYLTRANSFERASE GENOTYPE AND ORAL CANCER RISK$222,679
R01 · FY2004 · DE
Analysis of 5'UTR-Mediated Regulation of p53 Expression$241,063
R01 · FY2003 · CA
UDPGLUCURONOSYLTRANSFERASE GENOTYPE AND ORAL CANCER RISK$160,689
R01 · FY2003 · DE
UDPGLUCURONOSYLTRANSFERASE GENOTYPE AND ORAL CANCER RISK$60,163
R01 · FY2003 · DE
UDP GLUCURONOSYLTRANSFERASES, DETOXIFICATION OF NNK$315,615
P01 · FY2002 · CA
UDP GLUCURONOSYLTRANSFERASES, DETOXIFICATION OF NNK$315,615
P01 · FY2002 · CA
Analysis of 5'UTR-Mediated Regulation of p53 Expression$241,063
R01 · FY2002 · CA
UDPGLUCURONOSYLTRANSFERASE GENOTYPE AND ORAL CANCER RISK$215,688
R01 · FY2002 · DE
UDP GLUCURONOSYLTRANSFERASES, DETOXIFICATION OF NNK$315,615
P01 · FY2001 · CA
UDPGLUCURONOSYLTRANSFERASE GENOTYPE AND ORAL CANCER RISK$215,688
R01 · FY2001 · DE
UDP GLUCURONOSYLTRANSFERASES, DETOXIFICATION OF NNK$315,615
P01 · FY2000 · CA
MOLECULAR MARKERS OF ORAL CANCER RISK$306,929
R01 · FY2000 · DE
UDPGLUCURONOSYLTRANSFERASE GENOTYPE AND ORAL CANCER RISK$215,688
R01 · FY2000 · DE